Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review

The implementation of immune checkpoint-inhibitors (CPI) has significantly improved the prognosis of a subgroup of patients with urothelial bladder cancer (BC). Still, the majority of patients will progress or experience a recurrence on CPI monotherapy. The next generation of clinical trials is now...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Gerald B., Black, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575593/
https://www.ncbi.nlm.nih.gov/pubmed/34804844
http://dx.doi.org/10.21037/tau-20-1177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575593/
https://www.ncbi.nlm.nih.gov/pubmed/34804844
http://dx.doi.org/10.21037/tau-20-1177

Ejemplares similares